Content about Insulin

March 3, 2014

An international team led by researchers at the Broad Institute and Massachusetts General Hospital has identified mutations in a gene that can reduce the risk of developing Type 2 diabetes, even in people who have such risk factors as obesity and old age, the group announced Sunday.

CAMBRIDGE, Mass. — An international team led by researchers at the Broad Institute and Massachusetts General Hospital has identified mutations in a gene that can reduce the risk of developing Type 2 diabetes, even in people who have such risk factors as obesity and old age, the group announced Sunday. The results focus the search for developing novel therapeutic strategies for Type 2 diabetes — if a drug can be developed that mimics the protective effect of these mutations, it could open up new ways of preventing this devastating disease.

February 28, 2014

Pharma Supply earlier this week launched NeedleBay, a safe and easy method of organizing and dispensing insulin pen needles and medication.

WEST PALM BEACH, Fla. — Pharma Supply earlier this week launched NeedleBay, a safe and easy method of organizing and dispensing insulin pen needles and medication.

NeedleBay provides a highly visible, unique and simple “proof of use” reminder, which eliminates the risk of missed, or excess injections and associated medications. NeedleBay has been specially designed in consultation with healthcare professionals and those with diabetes, to enable the user to deploy disposable pen needles safely and to avoid the risk of needle pick injuries.

February 20, 2014

The Food and Drug Administration recently approved two "robotic pills," or pills that place an image camera or ingestible sensors into the gastrointestinal tract, according to a report published earlier this week by the Wall Street Journal.

NEW YORK — The Food and Drug Administration recently approved two "robotic pills," or pills that place an image camera or ingestible sensors into the gastrointestinal tract, according to a report published earlier this week by the Wall Street Journal

Other robotic pills still in development include one backed by Google — a pill that would replace injectable drugs, the report noted. 

February 12, 2014

America’s biopharmaceutical research companies currently are developing 180 new medicines to help the nearly 400 million people who have diabetes worldwide, the Pharmaceutical Research and Manufacturers of America announced Tuesday.

WASHINGTON — America’s biopharmaceutical research companies currently are developing 180 new medicines to help the nearly 400 million people who have diabetes worldwide, the Pharmaceutical Research and Manufacturers of America announced Tuesday. These medicines in development — all either in clinical trials or under review by the Food and Drug Administration — include 30 for type 1 diabetes, 100 for type 2 and 52 for diabetes-related conditions.

January 21, 2014

Novo Nordisk has launched a new insulin pen designed for children with diabetes.

NEW YORK — Novo Nordisk has launched a new insulin pen designed for children with diabetes.

The new NovoPen Echo is the first and only prefilled pen device in the United States that allows for half-unit dosing in combination with a memory function, the company said.

November 1, 2013

The Food and Drug Administration has approved two new insulin pens made by Novo Nordisk, the Danish drug maker said Friday.

PLAINSBORO, N.J. — The Food and Drug Administration has approved two new insulin pens made by Novo Nordisk, the Danish drug maker said Friday.

Novo Nordisk announced the FDA approval of Novolog FlexTouch (insulin aspart [rDNA origin]) and Levemir FlexTouch (insulin detemir [rDNA origin]).

August 21, 2013

The Food and Drug Administration has given the green light to an insulin pen made by Novo Nordisk for half-unit dosing, the drug maker said Wednesday.

PLAINSBORO, N.J. — The Food and Drug Administration has given the green light to an insulin pen made by Novo Nordisk for half-unit dosing, the drug maker said Wednesday.

June 21, 2013

Becton, Dickinson and Co. has launched a needle that it said would make insulin injections easier and faster for people with diabetes.

FRANKLIN LAKES, N.J. — Becton, Dickinson and Co. has launched a needle that it said would make insulin injections easier and faster for people with diabetes.

BD subsidiary BD Medical announced Friday the BD Ultra-Fine Nano 4-millimeter pen needle. The needle includes technology called EasyFlow, designed to aid faster and more comfortable injections, and product demonstrations will take place at the American Diabetes Association's 73rd annual Scientific Sessions in Chicago, lasting through next Tuesday.

April 5, 2013

Novo Nordisk has launched a diabetes awareness sweepstakes in which the winners get a free trip to the 2013 IndyCar finale, the Danish drug maker said.

BIRMINGHAM, Ala. — Novo Nordisk has launched a diabetes awareness sweepstakes in which the winners get a free trip to the 2013 IndyCar finale, the Danish drug maker said Friday.

The company announced that it had hired IZOD IndyCar Series Charlie Kimball as spokesman for its Race with Insulin contest. Kimball, the first licensed driver with diabetes to race at the highest level of the series, was diagnosed with the disease during a routine doctor visit in 2007 while racing in Europe and is a user of Novo Nordisk's NovoLog (insulin aspart [rDNA origin]).

February 19, 2013

Mylan and Biocon have a deal to develop and sell generic insulin-analog products for diabetes, Mylan said.

PITTSBURGH — Mylan and Biocon have a deal to develop and sell generic insulin-analog products for diabetes, Mylan said.

Under the deal, Mylan will have the rights to develop and market Biocon's Glargine, Lispro and Aspart, respectively generic versions of Sanofi's Lantus, Eli Lilly's Humalog and Novo Nordisk's NovoLog.

February 11, 2013

The Food and Drug Administration declined to approve two insulin products made by Danish drug maker Novo Nordisk, the company said Sunday.

BAGSVÆRD, Denmark — The Food and Drug Administration declined to approve two insulin products made by Danish drug maker Novo Nordisk, the company said Sunday.

Novo Nordisk said it received complete response letters from the FDA for Tresiba (insulin degludec) and Ryzodeg (insulin degludec and insulin aspart). The FDA issues a complete response letter when it has finished reviewing an application for a drug, but determines that the application can't be approved in its current form.

January 28, 2013

In August 2012, the American Association of Diabetes Educators highlighted recommendations and research confirming that more than one-third of the 25 million Americans with diabetes don’t take their insulin as prescribed. Collaborative Care recently had the opportunity to interview Jerry Meece, a pharmacist, certified diabetes educator and author of the AADE’s recommendations, about what pharmacists are — and should be — doing to address the problem.

In August 2012, the American Association of Diabetes Educators highlighted recommendations and research confirming that more than one-third of the 25 million Americans with diabetes don’t take their insulin as prescribed, with 20% intentionally skipping doses and many admitting they inject it in the wrong place or at the wrong time or use the wrong technique, and only 30% of patients receive formal insulin education.

January 22, 2013

During its annual business review Tuesday, Johnson & Johnson announced that the recent introduction of the OneTouch Verio Glucose testing platform represented one of the first diabetes care devices to alert and display high/low patterns that deliver more meaningful and actionable insights to help patients better understand and manage their diabetes.

NEW YORK — During its annual business review Tuesday, Johnson & Johnson announced that the recent introduction of the OneTouch Verio Glucose testing platform represented one of the first diabetes care devices to alert and display high/low patterns that deliver more meaningful and actionable insights to help patients better understand and manage their diabetes.

December 6, 2012

The Food and Drug Administration has given special designation to a treatment made by Biodel for patients with congenital hyperinsulinism, a rare disorder that affects children.

DANBURY, Conn. — The Food and Drug Administration has given special designation to a treatment made by Biodel for patients with congenital hyperinsulinism, a rare disorder that affects children.

Biodel announced that it had received orphan drug designation for glucagon to prevent hypoglycemia, or abnormally low blood sugar, in patients with CHI.

November 9, 2012

A Food and Drug Administration panel has voted to support two experimental insulin treatments made by Novo Nordisk, the Danish drug maker said Thursday.

BAGSVÆRD, Denmark — A Food and Drug Administration panel has voted to support two experimental insulin treatments made by Novo Nordisk, the Danish drug maker said Thursday.

Novo Nordisk said the FDA's Endocrinologic and Metabolic Drugs Advisory Committee had voted 8-to-4 in favor of approval for insulin degludec and a combination treatment containing insulin degludec and insulin aspart.

November 2, 2012

Eli Lilly is spending $140 million to expand its insulin manufacturing plant in Indianapolis, the drug maker said.

INDIANAPOLIS – Eli Lilly is spending $140 million to expand its insulin manufacturing plant in Indianapolis, the drug maker said.

Lilly said it would expand the plant by 80,000 sq. ft., saying it represented one of the most significant investments in its U.S. manufacturing operations in the past decade. Construction is expected to start immediately, with completion planned for March 2014.

October 19, 2012

Blood glucose monitoring is associated with reduced A1C levels and greater adherence to medication in Type 2 diabetes patients who do not take insulin, according to a study published in the September issue of Diabetes Technology & Therapeutics.

MILPITAS, Calif. — Blood glucose monitoring is associated with reduced A1C levels and greater adherence to medication in Type 2 diabetes patients who do not take insulin, according to a study published in the September issue of Diabetes Technology & Therapeutics.

October 3, 2012

A drug marketed by Boehringer Ingelheim Pharmaceuticals and Eli Lilly reduced blood sugar in elderly patients with Type 2 diabetes and in adults with diabetic nephropathy, according to results of three studies presented at a diabetes meeting in Berlin.

INDIANAPOLIS — A drug marketed by Boehringer Ingelheim Pharmaceuticals and Eli Lilly reduced blood sugar in elderly patients with Type 2 diabetes and in adults with diabetic nephropathy, according to results of three studies presented at a diabetes meeting in Berlin.

September 17, 2012

An organization focused on Type 1 diabetes research announced Monday the winners of a competition to find new ways to treat the disease.

NEW YORK — An organization focused on Type 1 diabetes research announced Monday the winners of a competition to find new ways to treat the disease.

August 14, 2012

NuSirt Sciences last week released a weight management product called NuShape and a product for healthy blood sugar called NuControl.

KNOXVILLE, Tenn. — NuSirt Sciences last week released a weight management product called NuShape and a product for healthy blood sugar called NuControl.

July 19, 2012

Roche on Wednesday announced that it has received clearance from the Food and Drug Administration for its Accu-Chek Combo system for insulin pump therapy.

INDIANAPOLIS — Roche on Wednesday announced that it has received clearance from the Food and Drug Administration for its Accu-Chek Combo system for insulin pump therapy.

June 26, 2012

The life of a patient with diabetes is a juggling act to maintain good glycemic control — from daily blood-glucose testing to eating healthy and staying active. This is a complex and sometimes inconvenient task requiring significant commitment. Today, the American Diabetes Association estimates 60 percent of diabetes patients do not adhere to their treatment regimen.

The life of a patient with diabetes is a juggling act to maintain good glycemic control — from daily blood-glucose testing to eating healthy and staying active. This is a complex and sometimes inconvenient task requiring significant commitment. Today, the American Diabetes Association estimates 60 percent of diabetes patients do not adhere to their treatment regimen.

June 21, 2012

An integrated wellness team approach to diabetes care can help patients not only improve their condition, but also lower their prescription costs, according to new research presented at the American Association of Clinical Endocrinologists’ 21st annual Scientific and Clinical Congress in Philadelphia.


An integrated wellness team approach to diabetes care can help patients not only improve their condition, but also lower their prescription costs, according to new research presented at the American Association of Clinical Endocrinologists’ 21st annual Scientific and Clinical Congress in Philadelphia.


June 21, 2012

Being overweight and obesity during adolescence are associated with a disproportionately higher risk for cardiovascular disease risk factors, especially prediabetes and diabetes, according to a study published in the journal Pediatrics.


Being overweight and obesity during adolescence are associated with a disproportionately higher risk for cardiovascular disease risk factors, especially prediabetes and diabetes, according to a study published in the journal Pediatrics.


June 14, 2012

A new Walgreens study released Thursday found that a pharmacist-led training and counseling program for patients receiving an injectable diabetes medication improved medication adherence by 24%.

DEERFIELD, Ill. — A new Walgreens study released Thursday found that a pharmacist-led training and counseling program for patients receiving an injectable diabetes medication improved medication adherence by 24%.